| 1. |
Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies[J]. Nat Rev Cancer, 2012, 12(9):599-612.
|
| 2. |
Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia[J]. Int J Hematol, 2013, 98(6):648-657.
|
| 3. |
Goldberg AD, Allis CD, Bernstein E. Epigenetics:a landscape takes shape[J]. Cell, 2007, 128(4):635-638.
|
| 4. |
Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia[J]. N Engl J Med, 2010, 363(25):2424-2433.
|
| 5. |
Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies:associations with prognosis and potential treatment strategies[J]. Leukemia, 2014, 28(9):1774-1783.
|
| 6. |
Thol F, Damm F, Luedeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia[J]. J Clin Oncol, 2011, 29(21):2889-2896.
|
| 7. |
Ribeiro AF, Pratcorona MA, Rockova V, et al. Mutant DNMT3A:a marker of poor prognosis in acute myeloid leukemia[J]. Blood, 2012, 119(24):5824-5831.
|
| 8. |
Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells[J]. Nature, 2011, 473(7347):394-397.
|
| 9. |
Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value[J]. Blood, 2010, 116(19):3923-3932.
|
| 10. |
Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia:a cancer and leukemia group B study[J]. J Clini Oncol, 2011, 29(10):1373-1381.
|
| 11. |
Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome[J]. N Engl J Med,2009, 361(11):1058-1066.
|
| 12. |
Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia:a Cancer and Leukemia Group B study[J]. J Clin Oncol, 2010, 28(14):2348-2355.
|
| 13. |
Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation[J]. Cancer Cell, 2010, 18(6):553-567.
|
| 14. |
Chowdhury R, Yeoh KK, Tian Y, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases[J]. EMBO Rep, 2011, 12(5):463-469.
|
| 15. |
Woods BA, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies[J]. Immunol Rev, 2015, 263(1):22-35.
|
| 16. |
Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia[J]. N Engl J Med, 2012, 366(12):1079-1089.
|
| 17. |
Tanaka S, Miyagi S, Sashida G, et al. EZH2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia[J]. Blood, 2012, 120(5):1107-1117.
|
| 18. |
Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes[J]. N Engl J Med, 2011, 364(26):2496-2506.
|
| 19. |
Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis[J]. Blood, 2011, 118(19):5227-5234.
|
| 20. |
Scheuermann JC, Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB[J]. Nature, 2010, 465(7295):243-U138.
|
| 21. |
Abdel-Wahab O, Adli M, Lafave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-Mediated gene repression[J]. Cancer Cell, 2012, 22(2):180-193.
|
| 22. |
Dawson MA, Bannister AJ, Göttgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin[J]. Nature, 2009, 461(7265):819-822.
|
| 23. |
Liu F, Zhao XY, Perna F, et al. JAK2V617F-Mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation[J]. Cancer Cell, 2011, 19(2):283-294.
|
| 24. |
Boukarabila H, Saurin AJ, Batsche EA, et al. The PRC1 polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation[J]. Genes Dev, 2009, 23(10):1195-1206.
|
| 25. |
Dinardo CD, Patel KP, Garcia-Manero G, et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents[J]. Leuk Lymphoma, 2014, 55(8):1925-1929.
|
| 26. |
Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J]. Leukemia, 2014, 28(1):78-87.
|
| 27. |
Momparler RL, Côté S, Momparler LF, et al. Epigenetic therapy of acute myeloid leukemia using 5-aza-2›-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation[J]. Clin Epigenetics, 2014, 6(1):19.
|
| 28. |
Roboz GJ. Epigenetic targeting and personalized approaches for AML[J]. Hematology Am Soc Hematol Educ Program, 2014, 2014(1):44-51.
|
| 29. |
Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes:results of the US Leukemia Intergroup trial E1905[J]. J Clin Oncol, 2014, 32(12):1242-1248.
|
